Cervomed announces publications in major peer-reviewed journals that inform on potential of neflamapimod as a disease-modifying therapy for the major dementias

Final publication in neurology® of phase 2a results stratified by plasma phosphorylated tau status at baseline strengthens the case for progressing neflamapimod as a disease-modifying treatment for dementia with lewy bodies research highlight article in molecular neurodegeneration comments that through acting on cholinergic degeneration neflamapimod has potential to have disease-modifying effects in both dementia with lewy bodies and alzheimer's disease boston , oct. 24, 2023 /prnewswire/ -- cervomed inc. (nasdaq: crvo), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for dementia with lewy bodies (dlb) and alzheimer's disease (ad): alam jj, maruff p, doctrow s, chu h-m, conway j, gomperts sn, teunissen c. association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with lewy bodies.
CRVO Ratings Summary
CRVO Quant Ranking